Transdermal Scopolamine

Global Market Trajectory & Analytics

MCP16073

EXECUTIVE ENGAGEMENTS

POOL

382
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

76
Interactions with Platform & by Email

PARTICIPANTS

13
Unique # Participated

VALIDATIONS

6
Responses Validated*

COMPANIES

41
Responses Validated*
* Login for a full stack data experience

DATE

APR 2021

TABLES

32

PAGES

103

EDITION

7

PRICE

USD 4950

CODE

MCP16073


COMPETITIVE METRICS

COMPANY

RANK & SHARE

D S N T

% *

Baxter International, Inc.

Login Required

Caleb Pharmaceuticals, Inc.

Login Required

Myungmoon Pharma Co. Ltd.

Login Required

Perrigo Company

Login Required

SUBMIT
* D = Dominant; S = Strong; N = Niche; T = Trivial (< 1%)
* Validated participants will receive complimentary Cluster data by email
Note: Best viewed in Landscape Mode
VIEW ENTIRE POOL OF 41 COMPETITORS

Sign-in with email to View Deeper Validated Engagement Details -

  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Transdermal Scopolamine estimated at US$368.7 Million in the year 2020, is projected to reach a revised size of US$528.5 Million by 2027, growing at a CAGR of 5.3% over the period 2020-2027.
The Transdermal Scopolamine market in the U.S. is estimated at US$108.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$93.2 Million by the year 2027 trailing a CAGR of 4.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5% and 4.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

SELECT PLAYERS

Alchem International; Alkaloids of Australia; ALZA Corporation; Baxter International Inc.; Caleb Pharmaceuticals Inc; Centroflora-Cms; Fine Chemicals Corporation; GlaxoSmithKline Plc; Myungmoon Pharma Co. Ltd.; Novartis AG; Perrigo Co. Plc; Phytex Australia

SEGMENTS

» Segment (Transdermal Scopolamine)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World Historic Review for Transdermal Scopolamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
USA Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CANADA
Canada Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
JAPAN
Japan Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
CHINA
China Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
China Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
EUROPE
Europe Current & Future Analysis for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe Historic Review for Transdermal Scopolamine by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Transdermal Scopolamine by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
FRANCE
France Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
France Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
GERMANY
Germany Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ITALY
Italy Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UK Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Transdermal Scopolamine by Segment - Transdermal Scopolamine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Transdermal Scopolamine by Segment - Transdermal Scopolamine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
Total Companies Profiled: 41

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com